TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Dose Range Study of CD5789 in Acne Vulgaris

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female participant, 12 to 35 years old with the following characteristics:~* Facial acne severity grade of the following:~  * Stratum 1: IGA score of 3 or 4~ * Stratum 2: IGA score of 4~ * Stratum 3: IGA score of 3 or 4~* A minimum of 30 non-inflammatory lesions and fulfills the criteria of one of the following strata:~  * Stratum 1: A minimum of 20 but not more than 40 inflammatory lesions, and a maximum of one nodule on the face.~ * Stratum 2: More than 40 inflammatory lesions, and up to four nodules on the face.~ * Stratum 3: Participants of Japanese origin with at least 20 inflammatory lesions and up to four nodules on the face.~    * Note: Participants of Japanese origin will not be included in Stratum 1 or Stratum 2. Japanese origin is defined as all four grandparents were born in Japan.~Exclusion Criteria:~* The presence of severe forms of acne (acne conglobata, acne fulminans) or secondary acne form (chloracne, drug-induced acne, etc.)~* Any uncontrolled or serious disease, or any medical or surgical condition, that may either interfere with the interpretation of the clinical trial results and/or put the participant at significant risk (according to the Investigator's judgment) if the participant participates in the clinical trial.~* Known or suspected allergies or sensitivities to any components of any of the study drugs.~* Current participation in any other clinical trial of a drug or device OR past participation within the 30 days prior to the Baseline visit.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- CD5789 25 mcg/g Cream (Type: EXPERIMENTAL): Participants randomized in stratum 1, 2 and 3 were applied with 25 mcg/g CD5789 cream, once daily for 12 weeks.
- CD5789 50 mcg/g Cream (Type: EXPERIMENTAL): Participants randomized in stratum 1, 2 and 3 were applied with 50 mcg/g CD5789 50 once daily for 12 weeks.
- CD5789 100 mcg/g Cream (Type: ACTIVE_COMPARATOR): Participants randomized in stratum 1, 2 and 3 were applied with 100 mcg/g CD5789 cream, once daily for 12 weeks.
- Tazarotene 0.1% Gel (Type: PLACEBO_COMPARATOR): Participants randomized in stratum 1 and 2 were applied with Tazarotene 0.1% Gel, once daily for 12 weeks.
- Vehicle Cream (Type: EXPERIMENTAL): Participants randomized in stratum 1, 2 and 3 were applied with Vehicle Cream once daily for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment Simplification by Darunavir/Ritonavir 800/100 mg Once a Day Versus a Triple Combination Therapy With Darunavir/Ritonavir

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with documented HIV-1 infection~* Patients currently receiving HAART for at least 24 weeks~* Plasma viral load \< 50 copies/mL for at least 24 weeks prior to screening (two results must be documented)~* Patients taking the same antiretroviral combination for at least 8 weeks before screening~* Patients and physician's preference to change the current HAART regimen for reasons of simplification and/or toxicity~* CD4 \> 100/mm3 at the start of HAART and \> 200/mm3 at screening.~Exclusion Criteria:~* No history of virological failure defined as two consecutive plasma HIV-1 RNA \> 500 copies/mL while on previous or current antiretroviral therapy~* No history of any primary PI mutations as defined by the IAS-USA guidelines 2006~* No patients co-infected with hepatitis B~* No pregnant or breastfeeding women~* No active clinically significant disease or life threatening disease or findings during screening of medical history or physical examination that, in the investigator's opinion, would compromise the patient's safety or outcome of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- darunavir monotherapy (Type: EXPERIMENTAL): darunavir (DRV, TMC114) 800 mg qd (2 x 400 mg tablet) monotherapy for 144 weeks
- darunavir + 2 NRTI (Type: EXPERIMENTAL): darunavir (DRV, TMC114) 800 mg qd (2 x 400 mg tablet) + 2 NRTI for 144 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Acute Lymphoblastic Leukemia or Aggressive Lymphoma With Relapse in Central Nervous System With Depocyt

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* proven diagnosis of ALL or very aggressive Non-Hodgkin-Lymphoma (Burkitt/Burkitt-like) and CNS relapse~* CNS involvement demonstrated by a positive ventricular or lumbar CSF cytology or characteristic signs and symptoms of neoplastic meningitis plus an MRI or CT scan indicating the presence of meningeal involvement~* in combined relapse in CNS and other locations: systemic therapy with CNS active drugs can be postponed for at least 2 weeks~* Karnofsky Performance Score is \> or = 60%~* 18 years of age or older~* free of uncontrolled infection~* recovered from any grade III / IV toxicities attributable to prior treatment with the exception of hematotoxicity~* patient not pregnant or breast feeding and effective methods to prevent pregnancy~* free from severe heart, lung, liver or kidney dysfunction~* written informed consent~Exclusion Criteria:~* failed to respond (as defined by no clearance of the CSF) to \> 1 dose of prior i.th. MTX or ARAC or triple therapy~* history of neurotoxicity (grade III - IV) attributed to i.th. or systemic HD therapy with MTX or ARAC~* prior CNS relapse \< 1 month before

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Only 1 arm (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Between 12 and 75 years of age, inclusive.~* Body weight at least 40 kg with a Body Mass Index \< 45~* PAH that is either idiopathic/heritable; associated with repaired congenital systemic-to-pulmonary shunts (repaired ≥ 5 years); associated with collagen vascular disease; associated with HIV.~* Previous testing (e.g., right heart catheterization, echocardiography) consistent with the diagnosis of PAH.~* Baseline 6-minute walk distance between 200 and 425 meters, inclusive.~* Reliable and cooperative with protocol requirements.~Exclusion Criteria:~* Nursing or pregnant.~* Currently receiving an endothelin receptor antagonist, a phosphodiesterase-5 inhibitor, or prostacyclin within 30 days of Baseline.~* PAH due to conditions other than noted in the above inclusion criteria.~* History of uncontrolled sleep apnea, renal insufficiency, anemia, left sided heart disease, uncontrolled systemic hypertension, or parenchymal lung disease.~* Use of an investigational drug within 30 days of Baseline.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- UT-15C (oral treprositnil) (Type: ACTIVE_COMPARATOR): Subjects receive UT-15C (oral treprostinil) twice daily.
- Placebo (Type: PLACEBO_COMPARATOR): Subjects receive placebo (sugar pill) twice daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Anti-inflammatory Effect of Therapeutic Hypothermia in Out-hospital Cardiac Arrest Patients With Cardiogenic Shock

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 18-100 years~* Cardiogenic sock including initial lactate level \>18 mg/dL, necessary of vasopressor to keep mean artery pressure \>65mmHg after adequate fluid supply, and signs of reduced cardiac output including disturbance consciousness, cold limbs, decreased urine output, acute pulmonary congestion and so on.~Exclusion Criteria:~* Patient or family refuse~* Metastatic cancer~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: t

Study Arms:
- Therapeutic hypothermia group (Type: EXPERIMENTAL): Anti-inflammatory effect of therapeutic hypothermia. The hypothesis is anti-inflammatory effect triggered by IL-6 trans-signaling
- Control group (Type: NO_INTERVENTION): No therapeutic hypothermia for controlled data.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Zushima Plaster for Treating Knee Osteoarthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Ages 40-75;~* Unilateral or bilateral knee OA, confirmed radiographically;~* Patients taking oral NSAIDs prior to the breakthrough period will be permitted;~* VAS pain score is or above 20mm.~Exclusion Criteria:~* Knee is swollen and hot;~* Allergic to any ingredient in Girald Daphne Bark Plaster (Girald Daphne Bark, Lithargite, Linseed oil, Red lead) ;~* Congestive Heart Failure and Edema;~* Advanced renal disease;~* Knee joint skin is burst or skin disease or allergies.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- High dose group (Type: ACTIVE_COMPARATOR): High dose of Zushima plaster: a piece of Zushima plaster will be used topically for each knee for 24h per day.~Eligible subjects will use a piece of Zushima plaster topically for each knee for 24h per day.
- Low dose group (Type: ACTIVE_COMPARATOR): Low dose of Zushima plaster: a piece of Zushima plaster will be used topically for each knee for 12h per day.~Eligible subjects will use a piece of Zushima plaster topically for each knee for 12h per day.
- Controlled group (Type: ACTIVE_COMPARATOR): Indometacin Cataplasms will be used topically on the knee for 24h per day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Eastern cooperative oncology group performance status (ECOG PS) score: 0-2 points~* Pathological diagnosis of oral squamous cell carcinoma (including tongue, gums, cheeks, mouth floor, hard palate, posterior molar region)~* Clinical stage of III/IVA (AJCC 2018)~* Blood routine: white blood cells\> 3,000/mm3, hemoglobin\> 8g/L, platelets\> 80,000/mm3~* Liver function: Alanine Transaminase/Aspartate Transaminase \<2.5 times the upper limit of normal, bilirubin \<1.5 times the upper limit of normal~* Renal function: serum creatinine \<1.5 times the upper limit of normal~* Sign the informed consent~Exclusion Criteria:~* There are still unresolved toxic reactions above CTCAE level 2 caused by previous anti-cancer treatment~* Obvious cardiovascular abnormalities \[such as myocardial infarction, superior vena cava syndrome, heart disease of grade 2 or higher diagnosed according to the classification criteria of the New York Heart Association (NYHA) 3 months before enrollment\]~* Active severe clinical infection (\> CTCAE 5.0 version 2 infection)~* Difficult to control hypertension (systolic blood pressure\> 150 mmHg and / or diastolic blood pressure\> 90 mmHg) or cardiovascular disease with clinical significance (such as activity)-such as cerebrovascular accident (≤ 6 months before randomization), myocardial infarction (≤6 months before randomization), unstable angina, New York Cardiology Society (NYHA Appendix 5) congestive heart failure grade II or above, or severe arrhythmia that cannot be controlled with drugs or has potential impact on experimental treatment~* Women during pregnancy or lactation~* Participated in other clinical studies within 30 days before enrollment~* Other circumstances that the investigator thinks are not suitable for participating in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Inductive therapy (Type: OTHER): Inductive therapy with Camrelizumab and Apatinib, followed by radical surgery and post-operative radiotherapy/chemoradiotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Severe Soft Tissue Bleeding Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects \>= 18 years of age, requiring elective, open, abdominal, retroperitoneal, pelvic or thoracic (non-cardiac) surgical procedures;~* Presence of an appropriate severe bleeding soft tissue Target Bleeding Site (TBS) as identified intra-operatively by the surgeon;~* Subjects must be willing to participate in the study, and provide written informed consent.~Exclusion Criteria:~* Subjects with any intra-operative findings identified by the surgeon that may preclude conduct of the study procedure;~* Bleeding site is from large defects in arteries or veins where the injured vascular wall requires repair with maintenance of vessel patency and which would result in persistent exposure of the FP to blood flow and pressure during healing and absorption of the product;~* Subject with TBS within an actively infected field;~* Bleeding site is in, around, or in proximity to foramina in bone, or areas of bony confine;~* Subjects with known intolerance to blood products or to one of the components of the study product;~* Subjects unwilling to receive blood products;~* Subjects with known immunodeficiency diseases (including known HIV);~* Subjects who are known, current alcohol and / or drug abusers;~* Subjects who have participated in another investigational drug or device research study within 30 days of enrollment;~* Female subjects who are pregnant or nursing.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fibrin Pad (Type: EXPERIMENTAL): None
- Standard of Care (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B Infection and Positive for Hepatitis B E Antigen

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
* Male and female subjects =/\> 16 years of age (or minimum age required in a given country) with history of chronic hepatitis B infection;~* Documentation of positive Hepatitis B e antigen (HBeAg) status.;~* The absence of coinfection with immunodeficiency virus (HIV), hepatitis C virus (HCV) or hepatitis D virus (HDV);~* The absence of other forms of liver disease e.g., alcoholic, autoimmune, biliary disease;~* Less than 12 weeks prior therapy with nucleoside or nucleotide analogue antiviral agents with activity against hepatitis B (e.g., adefovir, famciclovir and lamivudine)

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Postpartum Pre-exposure Prophylaxis (PrEP) Study to Evaluate an Adherence Promotion Package for Postpartum Women on PrEP

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Currently enrolled in PrEP-PP study and on PrEP~2. 18+ years old~3. confirmed HIV-negative (confirmed with a 4th generation antigen HIV test)~4. confirmed to be postpartum (1-6 months postpartum)~5. confirmed to currently have a male partner~6. confirmed to have a cell phone that can read and respond to SMS/Whatsapp messages~Exclusion Criteria:~Failure to meet all of inclusion criteria

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Intervention (Type: EXPERIMENTAL): HIV self-testing kits and counseling on use for participant and partner use + enhanced adherence counseling including urine tenofovir test to provide biofeedback in women using PrEP
- Control (Type: NO_INTERVENTION): Standard of care intervention including facility based HIV testing, referral for partner to attend facility for testing, and PrEP adherence counseling without biofeedback

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Panax Ginseng on the Cognitive Performance in Alzheimer's Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Alzheimer's disease~Exclusion Criteria:~* other neurologic disease

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 83 Years
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of TAS-114 in Combination With S-1 in Patients With Advanced Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Life expectancy of at least 3 months~* Histological or cytological documentation of advanced solid tumors~* ECOG Performance Status of ≤ 1 (ECOG: Eastern Cooperative Oncology Group)~* Adequate bone marrow, liver and renal function~* Women of childbearing potential and men must agree to use adequate contraception

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TAS-114/S-1 (Type: EXPERIMENTAL): TAS-114 plus S-1

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness and Safety of Once or Twice Daily Mometasone Nasal Spray Versus Amoxicillin Versus Placebo for Treatment of Acute Rhinosinusitis (Study P02683)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~Subjects must:~* have been diagnosed with acute rhinosinusitis~* have had signs and symptoms of rhinosinusitis for at least 7 but not more than 28 days prior to Baseline~* have had a major symptom score \>=5 and \<=12 at the Screening and Baseline, and no more than 3 of the 5 major individual symptoms were to be rated as severe~* be \>=12 years old~* be in good health overall and normal laboratory tests~* not be pregnant, intending to become pregnant or intending to impregnate.~Exclusion Criteria:~Subjects who:~* have a history of chronic rhinosinusitis or who had undergone sinus or nasal surgery for chronic rhinosinusitis in the 6 months prior to Screening~* have fever \>=101°F and/or persistent severe unilateral facial pain/tooth pain; and/or orbital or peri-orbital facial swelling; and/or dental involvement; and/or worsening symptoms after initial improvement~* have a history of symptomatic seasonal allergic rhinitis who were exposed to allergenic pollens~* have asthma with FEV1\<65% of predicted volume in the past 3 months or who have had an exacerbation within the past 30 days~* have nasal polyps, Kartagener's syndrome, and otitis or atrophic rhinitis~* have certain comorbid conditions or contraindications to certain drug therapies

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): MFNS once daily
- 2 (Type: EXPERIMENTAL): MFNS twice daily
- 3 (Type: ACTIVE_COMPARATOR): Amoxicillin
- 4 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete